Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 5, 2013, Pages 819-828

  Greupink, Rick ^a   Schreurs, Marieke ^a   Benne, Marina S ^a   Huisman, Maarten T ^b   Russel, Frans G M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

Author keywords

Clinical pharmacokinetics; Drug metabolism; Drug transport; Glibenclamide; Glyburide; Medication safety; Physiologically based pharmacokinetic modeling

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450; FLUCONAZOLE; GLIBENCLAMIDE; RIFAMPICIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG UPTAKE; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHYSICAL CHEMISTRY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VALIDATION STUDY;

EID: 84885141801     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.06.009     Document Type: Article

References (43)

1. Almond, L.M., Yang, J., Jamei, M., Tucker, G.T., Rostami-Hodjegan, A., 2009. Towards a quantitative framework for the prediction of DDIs arising from cytochrome P450 induction. Curr. Drug Metab. 10, 420-432.
2. Balant, L., 1981. Clinical pharmacokinetics of sulphonylurea hypoglycaemic drugs. Clin. Pharmacokinet. 6, 215-241.
3. Boileau, P., Wolfrum, C., Shih, D.Q., Yang, T.A., Wolkoff, A.W., Stoffel, M., 2002. Decreased glibenclamide uptake in hepatocytes of hepatocyte nuclear factor-1alpha-deficient mice: a mechanism for hypersensitivity to sulfonylurea therapy in patients with maturity-onset diabetes of the young, type 3 (MODY3). Diabetes 51 (Suppl. 3), S343-S348.
4. Bruggemann, R.J., Alffenaar, J.W., Blijlevens, N.M., Billaud, E.M., Kosterink, J.G., Verweij, P.E., Burger, D.M., 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis. 48, 1441-1458.
5. van de Steeg, E., Greupink, R., Schreurs, M., Nooijen, I.H., Verhoeckx, K.C., Hanemaaijer, R., Ripken, D., Monshouwer, M., Vlaming, M.L., Degroot, J., Verwei, M., Russel, F.G., Huisman, M.T., Wortelboer, H.M., 2013. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1. Drug Metab. Dispos. 41, 592-601.
6. Debruyne, D., Coquerel, A., 2001. Pharmacokinetics of antifungal agents in onychomycoses. Clin. Pharmacokinet. 40, 441-472.
7. Ekins, S., Kim, R.B., Leake, B.F., Dantzig, A.H., Schuetz, E.G., Lan, L.B., Yasuda, K., Shepard, R.L., Winter, M.A., Schuetz, J.D., Wikel, J.H., Wrighton, S.A., 2002. Threedimensional quantitative structure-activity relationships of inhibitors of Pglycoprotein. Mol. Pharmacol. 61, 964-973.
8. Gao, H., Steyn, S.J., Chang, G., Lin, J., 2010. Assessment of in silico models for fraction of unbound drug in human liver microsomes. Exp. Opin. Drug Metab. Toxicol. 6, 533-542.
9. Greupink, R., Dillen, L., Monshouwer, M., Huisman, M.T., Russel, F.G., 2011. Interaction of fluvastatin with the liver-specific Na+-dependent taurocholate cotransporting polypeptide (NTCP). Eur. J. Pharm. Sci. 44, 487-496.
10. Grube, M., Kock, K., Oswald, S., Draber, K., Meissner, K., Eckel, L., Bohm, M., Felix, S.B., Vogelgesang, S., Jedlitschky, G., Siegmund, W., Warzok, R., Kroemer, H.K., 2006. Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin. Pharmacol. Ther. 80, 607-620.
11. Hardman, J.G., Limbird, L.E., 2001. Goodman & Gilman's the Pharmacological Basis of Therapeutics.
12. Hilgendorf, C., Ahlin, G., Seithel, A., Artursson, P., Ungell, A.L., Karlsson, J., 2007. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35, 1333-1340.
13. Ho, R.H., Tirona, R.G., Leake, B.F., Glaeser, H., Lee, W., Lemke, C.J., Wang, Y., Kim, R.B., 2006. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806.
14. Howgate, E.M., Rowland, Y.K., Proctor, N.J., Tucker, G.T., Rostami-Hodjegan, A., 2006. Prediction of in vivo drug clearance from in vitro data. I: impact of interindividual variability. Xenobiotica 36, 473-497.
15. Jamei, M., Dickinson, G.L., Rostami-Hodjegan, A., 2009. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of 'bottom-up' vs 'top-down' recognition of covariates. Drug Metab. Pharmacokinet. 24, 53-75.
16. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G., Rostami-Hodjegan, A., 2009. The Simcyp population-based ADME simulator. Exp. Opin. Drug Metab. Toxicol. 5, 211-223.
17. Karttunen, P., Uusitupa, M., Nykanen, S., Robinson, J.D., Sipila, J., 1985. The pharmacokinetics of glibenclamide: a single dose comparison of four preparations in human volunteers. Int. J. Clin. Pharmacol. Ther. Toxicol. 23, 642-646.
18. Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., Brockmoller, J., 2005. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet. 44, 1209-1225.
19. Lilja, J.J., Niemi, M., Fredrikson, H., Neuvonen, P.J., 2007. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide. Br. J. Clin. Pharmacol. 63, 732-740.
20. Lobenberg, R., Kramer, J., Shah, V.P., Amidon, G.L., Dressman, J.B., 2000. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm. Res. 17, 439-444.
21. Morrison, P.J., Rogers, H.J., Spector, R.G., Bradbrook, I.D., John, V.A., 1982. Effect of pirprofen on glibenclamide kinetics and response. Br. J. Clin. Pharmacol. 14, 123-126.
22. Niemi, M., Backman, J.T., Neuvonen, M., Neuvonen, P.J., Kivisto, K.T., 2001. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide. Clin. Pharmacol. Ther. 69, 400-406.
23. Niemi, M., Pasanen, M.K., Neuvonen, P.J., 2006. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin. Pharmacol. Ther. 80, 356-366.
24. Olsen, K.M., Kearns, G.L., Kemp, S.F., 1995. Glyburide protein binding and the effect of albumin glycation in children, young adults, and older adults with diabetes. J. Clin. Pharmacol. 35, 739-745.
25. Pearson, J.G., 1985. Pharmacokinetics of glyburide. Am. J. Med. 79, 67-71.
26. Peters, S.A., 2012. Physiologically-Based Pharmacokinetic (PBPK) Modeling and Simulations: Principles, Methods, and Applications in the Pharmaceutical Industry. Wiley.
27. Peters, S.A., Ungell, A.L., Dolgos, H., 2009. Physiologically based pharmacokinetic (PBPK) modeling and simulation: applications in lead optimization. Curr. Opin. Drug Discov. Devel. 12, 509-518.
28. Petzinger, E., Fuckel, D., 1992. Evidence for a saturable, energy-dependent and carrier-mediated uptake of oral antidiabetics into rat hepatocytes. Eur. J. Pharmacol. 213, 381-391.
29. Rostami-Hodjegan, A., Tucker, G.T., 2007. Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nat. Rev. Drug Discov. 6, 140-148.
30. Roth, H.J., Eger, K., Troschuetz, R., 2012. Arzneistoffanalyse: Reaktivitaet-Stabilitaet-Analytik. Georg Thieme Verlag Stuttgart, New York.
31. Rowe, B.R., Thorpe, J., Barnett, A., 1992. Safety of fluconazole in women taking oral hypoglycaemic agents. Lancet 339, 255-256.
32. Rowland, Y.K., Jamei, M., Yang, J., Tucker, G.T., Rostami-Hodjegan, A., 2010. Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur. J. Pharm. Sci. 39, 298-309.
33. Rydberg, T., Jonsson, A., Karlsson, M.O., Melander, A., 1997. Concentration-effect relations of glibenclamide and its active metabolites in man: modelling of pharmacokinetics and pharmacodynamics. Br. J. Clin. Pharmacol. 43, 373-381.
34. Schelleman, H., Bilker, W.B., Brensinger, C.M., Wan, F., Hennessy, S., 2010. Antiinfectives and the risk of severe hypoglycemia in users of glipizide or glyburide. Clin. Pharmacol. Ther. 88, 214-222.
35. Tirkkonen, T., Heikkila, P., Huupponen, R., Laine, K., 2010. Potential CYP2C9-mediated drug-drug interactions in hospitalized type 2 diabetes mellitus patients treated with the sulphonylureas glibenclamide, glimepiride or glipizide. J. Intern. Med. 268, 359-366.
36. Wei, H., Lobenberg, R., 2006. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29, 45-52.
37. Wei, H., Dalton, C., Di, M.M., Kanfer, I., Lobenberg, R., 2008. Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption. Eur. J. Pharm. Biopharm. 69, 1046-1056.
38. Yang, J., Jamei, M., Heydari, A., Yeo, K.R., de la, T.R., Farre, M., Tucker, G.T., Rostami-Hodjegan, A., 2006. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol. 20, 842-849.
39. Yu, L.X., Lipka, E., Crison, J.R., Amidon, G.L., 1996a. Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. Adv. Drug Deliv. Rev. 19, 359-376.
40. Yu, L.X., Crison, J.R., Amidon, G.L., 1996. Compartmental Transit and Dispersion Model Analysis of Small Intestinal Transit Flow in Humans, pp. 111-118.
41. Zharikova, O.L., Fokina, V.M., Nanovskaya, T.N., Hill, R.A., Mattison, D.R., Hankins, G.D., Ahmed, M.S., 2009. Identification of the major human hepatic and placental enzymes responsible for the biotransformation of glyburide. Biochem. Pharmacol. 78, 1483-1490.
42. Zheng, H.X., Huang, Y., Frassetto, L.A., Benet, L.Z., 2009. Elucidating rifampin's inducing and inhibiting effects on glyburide pharmacokinetics and blood glucose in healthy volunteers: unmasking the differential effects of enzyme induction and transporter inhibition for a drug and its primary metabolite. Clin. Pharmacol. Ther. 85, 78-85.
43. Zhou, L., Naraharisetti, S.B., Liu, L., Wang, H., Lin, Y.S., Isoherranen, N., Unadkat, J.D., Hebert, M.F., Mao, Q., 2010. Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm. Drug Dispos. 31, 228-242.